Impact of new technologies on diabetes care.

作者: Elisa Giani , Andrea Enzo Scaramuzza , Gian Vincenzo Zuccotti

DOI: 10.4239/WJD.V6.I8.999

关键词:

摘要: Technologies for diabetes management, such as continuous subcutaneous insulin infusion (CSII) and glucose monitoring (CGM) systems, have improved remarkably over the last decades. These developments are impacting capacity to achieve recommended hemoglobin A1c levels assisting in preventing development progression of micro- macro vascular complications. While improvements metabolic control decreases risk severe moderate hypoglycemia been described with use these technologies, large epidemiological international studies show that many patients still unable meet their glycemic goals, even when technologies used. This editorial will review impact technology on control, quality life children youth type 1 diabetes. reviewed include CSII, CGM systems sensor-augmented pumps. In addition, usefulness advanced functions bolus profiles, calculators threshold-suspend features be also discussed. Moreover, current explore challenges using technologies. Indeed, despite evidence currently available potential benefits report barriers them. Finally this article highlight importance future tailored toward overcome optimizing avoiding hypoglycemia.

参考文章(40)
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, None, Continuous glucose monitoring and intensive treatment of type 1 diabetes. The New England Journal of Medicine. ,vol. 359, pp. 1464- 1476 ,(2008) , 10.1056/NEJMOA0805017
Olga Kordonouri, Reinhard Hartmann, Ewa Pankowska, Birgit Rami, Thomas Kapellen, Régis Coutant, Karin Lange, Thomas Danne, Sensor augmented pump therapy from onset of type 1 diabetes: late follow‐up results of the Pediatric Onset Study Pediatric Diabetes. ,vol. 13, pp. 515- 518 ,(2012) , 10.1111/J.1399-5448.2012.00863.X
Elisabeth B Haberl, Padmini Ranasinghe, Nisa Maruthur, Yong Suh, Zack Berger, Lisa M Wilson, Sherita Hill Golden, Todd Brown, Hsin-Chieh Yeh, Eric B Bass, Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Agency for Healthcare Research and Quality (US). ,(2012)
Diabetes Control and Complications Trial, None, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine. ,vol. 353, pp. 2643- 2653 ,(2005) , 10.1056/NEJMOA052187
A. Liberman, B. Buckingham, M. Phillip, Diabetes technology and the human factor. International Journal of Clinical Practice. ,vol. 66, pp. 83- 90 ,(2011) , 10.1111/J.1742-1241.2010.02583.X
Asma Deeb, Samar Abu-Awad, Salima Abood, Mohamed El-Abiary, Jamal Al-Jubeh, Hana Yousef, Laila AbdelRahman, Ahlam Al Hajeri, Huda Mustafa, Important determinants of diabetes control in insulin pump therapy in patients with type 1 diabetes mellitus. Diabetes Technology & Therapeutics. ,vol. 17, pp. 166- 170 ,(2015) , 10.1089/DIA.2014.0224
Bruce A. Buckingham, Fraser Cameron, Peter Calhoun, David M. Maahs, Darrell M. Wilson, H. Peter Chase, B. Wayne Bequette, John Lum, Judy Sibayan, Roy W. Beck, Craig Kollman, Outpatient Safety Assessment of an In-Home Predictive Low-Glucose Suspend System with Type 1 Diabetes Subjects at Elevated Risk of Nocturnal Hypoglycemia Diabetes Technology & Therapeutics. ,vol. 15, pp. 622- 627 ,(2013) , 10.1089/DIA.2013.0040
John C. Pickup, Insulin-Pump Therapy for Type 1 Diabetes Mellitus The New England Journal of Medicine. ,vol. 366, pp. 1616- 1624 ,(2012) , 10.1056/NEJMCT1113948
Daniela Bruttomesso, Silvana Costa, Aldo Baritussio, Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes-metabolism Research and Reviews. ,vol. 25, pp. 99- 111 ,(2009) , 10.1002/DMRR.931